
1. eur j health econ. 2018 dec;19(9):1365-1374. doi: 10.1007/s10198-018-0980-4. epub
2018 apr 25.

economic evaluation zepatier management hcv italian
scenario.

rolli fr(1), ruggeri m(1), kheiraoui f(2)(3), drago c(4), basile m(5), favaretti 
c(3), cicchetti a(1).

author information: 
(1)catholic university sacred heart, largo francesco vito 1, 00186, rome,
italy.
(2)istituto di sanità pubblica, sezione igiene, catholic university sacred
heart, rome, italy.
(3)vihtali, value health technology academy leadership innovation 
spin-off catholic university sacred heart, rome, italy.
(4)"nicolò cusano" university, rome, italy.
(5)catholic university sacred heart, largo francesco vito 1, 00186, rome,
italy. michele.basile@unicatt.it.

background: hepatitis c virus (hcv) major health issue worldwide. new
generation direct-active antiviral medications epoch-making turning
point management hcv infections.
objective: conducing cost-effectiveness analysis comparing combination of
elbasvir/grazoprevir sofosbuvir + pegylated interferon/ribavirin the
management hcv patients (even initial stages fibrosis).
methods: markov model built natural history disease assess
the efficacy alternatives. outcomes expressed terms quality 
adjusted life-years (qalys) result terms incremental cost-effectiveness
ratio).
results: elbasvir/grazoprevir implies expenditure €21,104,253.74 a
gain 19,287.90 qalys sofosbuvir + pegylated interferon/ribavirin implies
an expenditure €31,904,410.11 gain 18,855.96 qalys.
elbasvir/grazoprevir thus dominant strategy.
conclusion: consideration given opportunity cost treating
patients lower degree fibrosis (f0-f2).

doi: 10.1007/s10198-018-0980-4 
pmid: 29696459  [indexed medline]

